New review shows statins remain first-line therapy in MASLD, while PCSK9 inhibitors offer potential but require more evidence. Learn more about evolving treatment guidance.

Heart doctors are capturing images of the inside of heart arteries, helping them watch plaque respond to cholesterol drugs in ...

MetaDComprehensive umbrella review maps 227 non-genetic miscarriage risk factors, identifying 45 with suggestive evidence and ...

The Portfolio Diet is a plant-based eating system which Dr. David Jenkins designed to help people decrease their "bad" LDL ...

You might have high LDL cholesterol and not even know it. We spoke to experts about how to monitor this health stat so you ...

A review article discussed the expanding role of biologics in treating components of metabolic syndrome, including glucagon-like peptide 1 (GLP-1) analogs for type 2 diabetes and obesity and ...

Surviving longer and remaining healthier in later life is influenced by many factors beyond classical blood lipids. A growing ...

A recent review concluded The PREVENT equations provide updated risk models for assessing cardiovascular disease risk.

The study reveals that widely used heart-attack risk calculators fail to flag nearly half of those who will soon experience a ...

Coronary artery disease is one of the leading causes of morbidity and mortality worldwide. Although it can present with an ...

Enlicitide is an investigational oral PCSK9 inhibitor that has shown substantial reductions in LDL-C levels in patients with ...

It’s not just your imagination: your biological clock is reconfiguring how you experience the world, and your palate is one ...